Thymoquinone mitigates cardiac hypertrophy by activating adaptive autophagy via the PPAR‑γ/14‑3‑3γ pathway
International Journal of Molecular Medicine · 2025
DOI: 10.3892/ijmm.2025.5500 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Medicine, 2025. Verfasst von Rong-Bin Qiu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Surgery, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi 330006, P.R. Chi…. Hauptthemen laut MEDLINE: Autophagy, Cardiomegaly, Benzoquinones, PPAR gamma. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Thymoquinone (TQ), the principal active compound derived from the black seed plant, has been extensively utilized in traditional medicine for treating various ailments. Despite its widespread use, its therapeutic mechanisms in the context of cardiac hypertrophy remain insufficiently understood. The present study focused on assessing the efficacy of TQ in mitigating cardiac hypertrophy while identifying its specific protective pathways. Through a combination of in vivo experiments utilizing a mouse model of transverse aortic constriction (TAC) and in vitro studies utilizing an angiotensin II (AngII)‑induced hypertrophy model in H9C2 cells, the protective actions of TQ were comprehensively evaluated. The results revealed that TQ significantly attenuated TAC‑induced cardiac hypertrophy and improved overall cardiac function. In AngII‑induced H9C2 cells, pretreatment with TQ significantly reduced both cell hypertrophy and reactive oxygen species levels, while simultaneously promoting autophagy and limiting fibrosis. TQ was also found to increase the transcriptional activity of peroxisome proliferator‑activated receptor‑γ (PPAR‑γ), which interacted with 14‑3‑3γ protein, leading to autophagy activation and subsequent cellular protection. However, the protective autophagic effects were attenuated when PPAR‑γ activity was inhibited alongside pAD/14‑3‑3γ‑short hairpin RNA administration. The present findings demonstrate that TQ mitigates cardiac hypertrophy by modulating autophagy via the PPAR‑γ/14‑3‑3γ signaling axis, highlighting its therapeutic potential for cardiac hypertrophy treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Surgery, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi 330006, P.R. China.
- Department of Nursing, Gannan Health Vocational College, Ganzhou, Jiangxi 341000, P.R. China.
Zitieren
APA
Qiu, R. B., Zhao, S. T., Xu, Z. Q., Hu, L. J., Zeng, R. Y., Qiu, Z. C., Peng, H. Z., Zhou, L. F., Cao, Y. P., & Wan, L. (2025). Thymoquinone mitigates cardiac hypertrophy by activating adaptive autophagy via the PPAR‑γ/14‑3‑3γ pathway. International Journal of Molecular Medicine. https://doi.org/10.3892/ijmm.2025.5500
Vancouver
Qiu RB, Zhao ST, Xu ZQ, Hu LJ, Zeng RY, Qiu ZC, et al. Thymoquinone mitigates cardiac hypertrophy by activating adaptive autophagy via the PPAR‑γ/14‑3‑3γ pathway. International Journal of Molecular Medicine. 2025. doi:10.3892/ijmm.2025.5500
BibTeX
@article{Qiu2025,
author = {Qiu, Rong-Bin and Zhao, Shi-Tao and Xu, Zhi-Qiang and Hu, Li-Juan and Zeng, Rui-Yuan and Qiu, Zhi-Cong and Peng, Han-Zhi and Zhou, Lian-Fen and Cao, Yuan-Ping and Wan, Li},
title = {Thymoquinone mitigates cardiac hypertrophy by activating adaptive autophagy via the PPAR‑γ/14‑3‑3γ pathway},
journal = {International Journal of Molecular Medicine},
year = {2025},
doi = {10.3892/ijmm.2025.5500}
}
EUVIMED